Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.92 -4.65 (-4.21%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays ↗

October 27, 2021

It's much too early to count these companies out.

Via The Motley Fool

Could This Be the Next Blockbuster Indication for Eli Lilly? ↗

October 21, 2021

Eli Lilly and Incyte's Olumiant could be a groundbreaking therapy for patients with alopecia areata.

Via The Motley Fool

Incyte to Report Third Quarter Financial Results

October 13, 2021

From Incyte

Via Business Wire

Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo

October 02, 2021

From Incyte

Via Business Wire

Expert Ratings For Incyte ↗

September 23, 2021

Over the past 3 months, 5 analysts have published their opinion on Incyte (NASDAQ:

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗

October 01, 2021

Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...

Via Benzinga

Incyte Names New Member to Its Board of Directors

September 28, 2021

From Incyte

Via Business Wire

Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate ↗

September 27, 2021

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license...

Via Benzinga

Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America ↗

September 23, 2021

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin...

Via Benzinga

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

BriaCell's Survival Story Could Mean a Better Chance of Survival for Women Suffering from Breast Cancer ↗

September 23, 2021

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

September 23, 2021

Deutsche Bank reduced the price target for FedEx Corporation (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

Back To Back FDA Approval For Incyte - This Time For Jakafi In GVHD ↗

September 22, 2021

The FDA has approved Incyte Corporation's (NASDAQ: INCY) approved Jakafi (ruxolitinib) for chronic graft-versus-host disease (GVHD). The approval comes for...

Via Benzinga

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data ↗

September 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (...

Via Benzinga

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

September 22, 2021

From Incyte

Via Business Wire

Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start ↗

September 22, 2021

Find out what held these laggards back.

Via The Motley Fool

Topics Stocks

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

Incyte's Topical JAK Inhibitor Scores FDA Approval For Atopic Dermatitis ↗

September 22, 2021

The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate...

Via Benzinga

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

September 21, 2021

From Incyte

Via Business Wire

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data ↗

September 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...

Via Benzinga

Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada ↗

September 20, 2021

Health Canada has given conditional approval to Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma...

Via Benzinga

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

Price Over Earnings Overview: Incyte ↗

September 14, 2021

In the current market session, Incyte Inc. (NASDAQ:INCY) is trading at $72.46, after a 0.1% gain. However, over the past month, the stock fell by 4.23%, and in the...

Via Benzinga

Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

September 13, 2021

From Incyte

Via Business Wire

FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know ↗

September 02, 2021

The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR...

Via Benzinga

AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly ↗

September 01, 2021

AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq.

Via Investor's Business Daily

< Previous 1 2

...

19 20 21 22 23 24 25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.